Revision history of "Fluorescent marks for use in medical devices" (Q11207)

Jump to navigation Jump to search

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

12 March 2024

15 January 2024

11 June 2023

17 February 2023

2 July 2022

  • curprev 15:2615:26, 2 July 2022DG Regio talk contribs 48,007 bytes +28,103 Changed label, description and/or aliases in da, el, hr, ro, sk, mt, pt, fi, pl, sl, lt, lv, bg, hu, ga, sv, et, cs, nl, fr, de, it, es, and other parts: Adding translations: da, el, hr, ro, sk, mt, pt, fi, pl, sl, lt, lv, bg, hu, ga, sv, et,

24 June 2022

15 January 2022

14 January 2022

12 December 2021

2 December 2021

  • curprev 08:1408:14, 2 December 2021DG Regio talk contribs 15,426 bytes +1,361 Created claim: summary (P836): Das Projekt konzentriert sich auf F & E-Technologien zur Herstellung spezifischer Fluoreszenzmarken, sogenannte Tandemfluorchrome, die die Herstellung einer Gruppe von Produkten ermöglichen – In-vitro-Diagnostika (IVD) zur Identifizierung maligner, reaktiver und normaler Blutzellen in klinischen Proben mittels Durchflusszytometrie. Die Einhaltung der Anforderungen der Verordnung 21 CFR 820 wird die Möglichkeit der Registrierung neuer Produkte fü...
  • curprev 08:1408:14, 2 December 2021DG Regio talk contribs 14,065 bytes +111 Changed label, description and/or aliases in de: translated_label

28 November 2021

  • curprev 09:1209:12, 28 November 2021DG Regio talk contribs 13,954 bytes +1,414 Created claim: summary (P836): Le projet met l’accent sur les technologies de R & D pour la préparation de marques fluorescentes spécifiques, appelées fluorochromes tandems, qui permettront la production d’un groupe de produits — dispositifs médicaux de diagnostic in vitro (DIV) pour l’identification des cellules sanguines malignes, réactives et normales dans des échantillons cliniques par cytométrie de flux. Le respect des exigences de la règle 21 CFR 820 garantira la possib...
  • curprev 09:1209:12, 28 November 2021DG Regio talk contribs 12,540 bytes +141 Changed label, description and/or aliases in fr: translated_label

27 December 2020

28 October 2020

22 October 2020

  • curprev 15:2715:27, 22 October 2020DG Regio talk contribs 12,848 bytes +1,342 Created claim: summary (P836): The project is focused on R & D technologies for the preparation of specific fluorescent brands, called tandem fluorochromes, which will enable the production of a group of products – In vitro diagnostic (IVD) medical devices for the identification of malignant, reactive and normal blood cells in clinical samples using flow cytometry. Compliance with the requirements of regulation 21 CFR 820 will guarantee the possibility of registration of new...
  • curprev 15:2715:27, 22 October 2020DG Regio talk contribs 11,506 bytes −847 Removed claim: summary (P836): The project is aimed at R & D for the preparation of specific fluorescent marks, so-called tandem fluorochroms, to enable the production of a product group — In vitro diagnostic (IVD) medical devices to identify malignant, reactive and normal blood cells in clinical samples by flow cytometry. Compliance with the requirements of regulation 21 CFR 820 will guarantee the possibility of registering new products for clinical applications in global...
  • curprev 06:4306:43, 22 October 2020DG Regio talk contribs 12,353 bytes +103 Changed label, description and/or aliases in 1 language: translated_label
  • curprev 06:4306:43, 22 October 2020DG Regio talk contribs 12,250 bytes −103 Changed label, description and/or aliases in 1 language: remove_english_label

24 September 2020

22 September 2020

15 July 2020

6 June 2020

25 March 2020

19 March 2020

26 February 2020

  • curprev 07:3707:37, 26 February 2020DG Regio talk contribs 11,085 bytes +847 Created claim: summary (P836): The project is aimed at R & D for the preparation of specific fluorescent marks, so-called tandem fluorochroms, to enable the production of a product group — In vitro diagnostic (IVD) medical devices to identify malignant, reactive and normal blood cells in clinical samples by flow cytometry. Compliance with the requirements of regulation 21 CFR 820 will guarantee the possibility of registering new products for clinical applications in global ma...

17 February 2020

12 February 2020

6 February 2020

30 January 2020

28 January 2020

16 January 2020

10 January 2020